Ari Rosenberg on Muck Rack

Ari Rosenberg

New York
As seen in: Nature, PNAS, JAMA (The Journal of the American Medical Association), JAMA Oncology, JAMA: Journal of the American Medical Association, Cell Reports, Stem Cell Reports, MediaPost, CT Insider, Fairfield Citizen and
Mediapost Columnist, Digital Ad Sales Entrepreneur, Life long Viking Fan.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ari

Contact Ari, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Opinion: Religious leaders condemn ICE actions in Danbury

|
By Ari Rosenberg
| CT Insider Verified
The Association of Religious Communities (ARC) unequivocally condemns the recent escalation of ICE enforcement actions in the Greater Danbury area, including the detentions reported this week outside the Danbury courthouse and similar operations conducted last summer that left immigrant families living in fear.
Open in Who Shared Issue with article?

Opinion: Religious leaders condemn ICE actions in Danbury

|
By Ari Rosenberg
| Fairfield Citizen Verified
The Association of Religious Communities (ARC) unequivocally condemns the recent escalation of ICE enforcement actions in the Greater Danbury area, including the detentions reported this week outside the Danbury courthouse and similar operations conducted last summer that left immigrant families living in fear.
Open in Who Shared View Duplicates (9) Issue with article?

ASCO 2026 Head & Neck AND Sarcoma Highlights – Drs. Samantha Armstrong & Ari Rosenberg

|
By Samantha Armstrong, Ari Rosenberg
| oncbrothers.com
Nasopharyngeal Carcinoma: comparing carboplatin and cisplatin in induction and concurrent chemoradiation therapy. Can we extrapolate these findings to other head and neck cancers? Amivantamab in Head and Neck Cancer: Insights from the OrigAMI4 study, showcasing the efficacy of amivantamab in refractory settings, with an impressive overall response rate of 47%.
Open in Who Shared Issue with article?
See all 226 licensed articles (245 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified